| abstract |
Provided herein are modified immunoglobulins comprising an amyloid-reactive peptide linked to an antibody, as well as humanized antibodies and antibody-peptide fusion proteins that bind to human amyloid fibrils. Also provided herein are methods of treating amyloidosis by administering modified immunoglobulins, humanized antibodies, or antibody-peptide fusion proteins. [Selection drawing] Fig. 3 |